Table 1 Demographic and clinicopathological features of the 47 analyzed metastatic breast cancer patients
Age | |
 Median (range) | 62 (36–82) |
 < 70 years | 36 (77 %) |
 ≥ 70 years | 11 (23 %) |
ECOG PS, n (%) | Â |
 0 | 29 (62 %) |
 1 | 14 (29 %) |
 2 | 4 (9 %) |
Immunophenotype, n (%) | |
 Luminal-like | 25 (54 %) |
 HER2-positive | 11 (23 %) |
 Triple negative | 11 (23 %) |
Histotype, n (%) | |
 Ductal | 38 (84 %) |
 Lobular | 7 (16 %) |
Metastatic sites,a n (%) | |
 Bone | 29 (62 %) |
 Liver | 22 (47 %) |
 Lung | 16 (34 %) |
 CNS | 3 (6 %) |
Number of metastatic sites, n (%) | |
 1 | 16 (34 %) |
 ≥ 2 | 31 (66 %) |
Number of previous lines, n (%) | |
 0 | 15 (32 %) |
 1 | 9 (19 %) |
 ≥ 2 | 23 (49 %) |
Type of treatments received, n (%) | |
 Chemotherapy | 33 (70 %) |
 Endocrine therapy | 6 (13 %) |
 Chemotherapy and endocrine therapy | 5 (11 %) |
 Palliative care | 2 (6 %) |
 Anti-HER2 targeted therapy | 12 (26 %) |